Bicalutamide

Generic Name
Bicalutamide
Brand Names
Casodex
Drug Type
Small Molecule
Chemical Formula
C18H14F4N2O4S
CAS Number
90357-06-5
Unique Ingredient Identifier
A0Z3NAU9DP
Background

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

Indication

Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.

Associated Conditions
Metastatic stage D2 Prostatic carcinoma
Associated Therapies
-

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Not Applicable
Active, not recruiting
Conditions
Interventions
First Posted Date
2011-04-27
Last Posted Date
2024-05-24
Lead Sponsor
University of Chicago
Target Recruit Count
74
Registration Number
NCT01342367
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-02-03
Last Posted Date
2024-12-06
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
375
Registration Number
NCT01288911
Locations
🇷🇴

Site RO3042, Bucharest, RO, Romania

🇷🇴

Site RO3039, Bucharest, RO, Romania

🇷🇴

Site RO3035, Bucharest, Romania

and more 85 locations

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

First Posted Date
2010-12-02
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
108
Registration Number
NCT01251861
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

Carle Cancer Institute Normal, Normal, Illinois, United States

🇺🇸

Iowa Methodist Medical Center, Des Moines, Iowa, United States

and more 195 locations

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

First Posted Date
2010-12-01
Last Posted Date
2014-02-04
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
28
Registration Number
NCT01250717
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

First Posted Date
2010-09-14
Last Posted Date
2017-12-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT01200810
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

First Posted Date
2010-05-10
Last Posted Date
2018-02-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
211
Registration Number
NCT01120236
Locations
🇺🇸

Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Highlands Oncology Group-Rogers, Rogers, Arkansas, United States

and more 167 locations

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

First Posted Date
2010-01-15
Last Posted Date
2017-03-23
Lead Sponsor
Mayo Clinic
Target Recruit Count
18
Registration Number
NCT01050842
Locations
🇺🇸

Mayo Clinic In Arizona, Scottsdale, Arizona, United States

Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-01-08
Last Posted Date
2010-03-02
Lead Sponsor
Kremers Urban Development Company
Target Recruit Count
60
Registration Number
NCT01044706
Locations
🇨🇦

SFBC Anapharm, sainte-Foy, Quebec, Canada

Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-09-09
Last Posted Date
2009-09-09
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
60
Registration Number
NCT00973050
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-09-09
Last Posted Date
2009-09-09
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
60
Registration Number
NCT00972855
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath